Hims & Hers Health: growth title in telemedicine with explosive revenue growth
Hims & Hers Health $HIMS is one of the fastest-growing stocks of 2024, with its expansion into the weight-loss injections (GLP-1) segment and aggressive marketing strategy driving its stock up 150%.
Today Alibaba reported results that were very good, and it is clear that the company is still doing well. Shares rose 14% after the results. I bought the stock at the beginning of the year and am currently over 50% in profit, which makes me quite happy.
🚗 Mercedes-Benz announces bad results: profit down, lower sales and pressure on electric cars!
Mercedes-Benz $MBG.DE announced results for 2024 that didn't please too much. Profit dropped by 28 % to 10.4 billion euros, mainly due to lower sales in the key markets of Germany and China. The carmaker is now trying to adapt to the new reality and plans to cut costs by 2027 by 10 %,... Read more
Medtronic $MDT, a leading medical technology company, reported mixed Q3 results . Although earnings per share beat expectations, sales fell slightly short, mainly due to weaker demand for surgical devices. Shares fell more than 7% in response!
Both companies have very similar businesses and compete with each other. With $NVO, they may be at risk of tariffs that Trump might impose, and their drug may not be as popular in the US. Still, $NVO currently looks more interesting to me , which is why I've been shopping around this year. I think the stock is undervalued and the... Read more
Two nuclear power stocks that may benefit from Trump administration policies in 2025
Zobrazit další komentáře
Good news or bad news?
Hims & Hers Health: growth title in telemedicine with explosive revenue growth
Hims & Hers Health $HIMS is one of the fastest-growing stocks of 2024, with its expansion into the weight-loss injections (GLP-1) segment and aggressive marketing strategy driving its stock up 150%.
1. Rocketing revenue growth
- Q1: +46% | Q2: +52% | Q3: +72%
- Expected growth for Q4: up to 90%
-Demand...
Read more
Zobrazit další komentáře
- 25% is already a solid drop, but it may be a good time to buy.
Today Alibaba reported results that were very good, and it is clear that the company is still doing well. Shares rose 14% after the results. I bought the stock at the beginning of the year and am currently over 50% in profit, which makes me quite happy.
What do you think of $BABA'sresults ?
Zobrazit další komentáře
I don't invest in China. $BABA is growing solidly, but I just don't like the politics and their system.
🚗 Mercedes-Benz announces bad results: profit down, lower sales and pressure on electric cars!
Mercedes-Benz $MBG.DE announced results for 2024 that didn't please too much. Profit dropped by 28 % to 10.4 billion euros, mainly due to lower sales in the key markets of Germany and China. The carmaker is now trying to adapt to the new reality and plans to cut costs by 2027 by 10 %,...
Read more
Zobrazit další komentáře
Great company, however, I don't find European car companies interesting anymore, as they are really not doing well right now.
Apple launches iPhone 16e: A cheaper version of the iPhone 16 with Apple Intelligence support
From reviews to billions: advertising revenue and services as a path to growth
From reviews to billions: advertising revenue and services as a path to growth
AI supercomputer predicts these three stocks will grow in 2025
TRUMP AND HIS TARIFFS IMPACTING THE AUTO INDUSTRY
Read more
Zobrazit další komentáře
I have $P911.DE in my portfolio and that may be a pretty big deal for them, but I'll still hold.
💉 Medtronic under pressure: Weaker surgical device sales send shares down! 📉
Medtronic $MDT, a leading medical technology company, reported mixed Q3 results . Although earnings per share beat expectations, sales fell slightly short, mainly due to weaker demand for surgical devices. Shares fell more than 7% in response!
...Read more
Zobrazit další komentáře
I used to follow the company quite a bit and had it on my watchlist, but the performance is lousy, so I haven't bought and probably won't.
Investors, do you find $LLY or $NVObetter ?
Both companies have very similar businesses and compete with each other. With $NVO, they may be at risk of tariffs that Trump might impose, and their drug may not be as popular in the US. Still, $NVO currently looks more interesting to me , which is why I've been shopping around this year. I think the stock is undervalued and the...
Read more
Zobrazit další komentáře
Now, I think it is impossible to say who is better, because it will only be a few years later. But I'm also buying $NVO right now.
Nike in a tricky situation: partnership with Kim Kardashian to bring about a turnaround